7月15日，荣昌生物(09995.HK)盘中上涨5.39%，报86.95港元，成交额1.08亿港元。
消息面上，7月9日国家卫健委等三部门联合发布《国家基本药物目录（2026年版）》，荣昌生物自主研发的泰它西普被纳入"免疫系统用药"，系本次仅有的2款国产Ⅰ类生物创新药之一。新版目录将于9月1日实施，各级医疗机构须强制配备，有望打通基层市场准入，并为年底医保谈判铺路。泰它西普目前已获批系统性红斑狼疮、类风湿关节炎、重症肌无力、干燥综合征及IgA肾病5项适应症，覆盖千万级患者群体。同日生物科技板块整体走强，科伦博泰生物涨9.8%、康方生物涨8.4%、信达生物涨7.44%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.